Management of Moderate Arthritic Changes of the Symphysis Pubis
For moderate arthritic changes of the symphysis pubis with marginal osteophyte formation, begin with NSAIDs at maximum tolerated anti-inflammatory doses as first-line treatment, combined with activity modification and physical therapy or home exercises.
Initial Conservative Management
The management approach should follow a stepwise algorithm prioritizing non-surgical interventions:
First-Line Treatment
NSAIDs should be prescribed at full anti-inflammatory dosages as the primary pharmacologic intervention 1. This recommendation comes from established guidelines for inflammatory joint conditions, where NSAIDs demonstrate >70% ASAS20 response rates. Continuously weigh cardiovascular and gastrointestinal risks against benefits, particularly with chronic use.
Physical therapy or structured home exercise programs are recommended as essential non-pharmacologic interventions 1. While home exercises are more cost-effective and feasible, formal physical therapy may be necessary for patients requiring supervised rehabilitation.
Second-Line Options
If NSAIDs fail, are contraindicated, or poorly tolerated:
Analgesics (paracetamol or opioid-like medications) may be considered for residual pain 1, though evidence for efficacy in joint inflammation is limited.
Local glucocorticoid injections directed at the symphysis pubis may provide symptomatic relief 1. However, avoid long-term systemic glucocorticoids, as they lack evidence for sustained benefit in axial/joint disease and carry significant adverse effects.
Surgical Intervention for Refractory Cases
Surgery should be reserved for the approximately 5-10% of patients who fail conservative measures after adequate trial (typically 3-6 months minimum) 2.
Surgical Options (in order of current preference):
Endoscopic pubic symphysectomy - This has emerged as the preferred surgical approach 2. It allows adequate resection with minimal complications, preserves stability, and can address concomitant pathology (femoroacetabular impingement, adductor issues). Recent evidence shows good short-term outcomes with minimal morbidity.
Arthroscopically-assisted minimally invasive symphysioplasty - For refractory osteitis pubis, this technique involves remodeling symphysis end plates with autogenous fibrin support 3. A 2022 study showed excellent outcomes with mean NAHS improvement from 64.4 to 91.4 points and return to sport in all patients.
Pubic symphysis arthrodesis - Reserved for severe, refractory osteoarthritis cases 4. A 2024 study demonstrated clinical and radiographic improvement at one year in elderly patients, though this eliminates physiological joint mobility.
Semitendinosus tendon graft reconstruction - An emerging technique that preserves symphyseal mobility while providing stability 5. Shows promise for athletes with >30-point Harris Hip Score improvement and return to sport at 6-8 months.
Critical Pitfalls to Avoid
Do not use conventional synthetic DMARDs (methotrexate, sulfasalazine, leflunomide) for isolated symphysis pubis arthritis unless part of systemic inflammatory arthropathy like rheumatoid arthritis 1, 6. These are ineffective for mechanical/degenerative joint disease.
Rule out infection (osteomyelitis) before attributing symptoms solely to degenerative changes 7. Pubic symphysis osteomyelitis can mimic arthritis, particularly in immunosuppressed patients, diabetics, or those with recent pelvic surgery. Consider cross-sectional imaging (CT/MRI) and inflammatory markers if clinical suspicion exists.
Avoid premature surgical intervention - The vast majority of cases respond to conservative management. Surgery should only follow documented failure of adequate conservative therapy 8, 2.
Consider biomechanical factors - Degenerative changes often result from pelvic instability or abnormal mechanics 9. Address underlying causes (leg length discrepancy, sacroiliac dysfunction) to prevent recurrence.
The evidence strongly supports a conservative-first approach with escalation to minimally invasive surgical techniques only when medical management fails after appropriate trial duration.